20/20 BioLabs to Discuss FDA Advisory Committee Vote and Franchise Model Expansion
Event summary
- 20/20 BioLabs to host investor webinar on October 7, 2026, to discuss FDA advisory committee vote on GRAIL’s Galleri® MCED test and its implications for the broader multi-cancer early detection (MCED) category.
- CEO Jonathan Cohen to outline the company’s OneTest™ franchise model, which aims to expand commercial reach through independent regional laboratories.
- Preliminary interest from U.S. laboratories and new state funding for firefighter cancer screening to be highlighted.
- Company targeting Medicare reimbursement for MCED by the end of 2028.
The big picture
The FDA’s advisory committee vote on GRAIL’s Galleri® test sets a precedent for the broader MCED category, influencing regulatory and reimbursement strategies for competitors like 20/20 BioLabs. The company’s OneTest™ franchise model represents a strategic pivot toward decentralized commercial expansion, leveraging regional laboratories to scale without heavy infrastructure investment. Success in this model could redefine how early cancer detection tests are commercialized in the U.S.
What we're watching
- Regulatory Clarity
- How the FDA’s favorable vote on GRAIL’s Galleri® test will shape the regulatory path for 20/20 BioLabs’ OneTest™ for Cancer.
- Franchise Model Scalability
- Whether the OneTest™ franchise model can successfully expand commercial reach without requiring a national sales force.
- Reimbursement Timeline
- The pace at which 20/20 BioLabs can achieve Medicare reimbursement for MCED by the end of 2028.
Related topics